Immune cell therapy for hepatocellular carcinoma

Abstract Given the success of immune checkpoint inhibitors and chimeric antigen receptor (CAR) T cells in clinical settings, the host immune system plays an important role in the recognition and targeting of tumor cells in cancer immunotherapy. As a result, there have been numerous advancements in i...

Full description

Bibliographic Details
Main Authors: Eishiro Mizukoshi, Shuichi Kaneko
Format: Article
Language:English
Published: BMC 2019-05-01
Series:Journal of Hematology & Oncology
Subjects:
Online Access:http://link.springer.com/article/10.1186/s13045-019-0742-5
Description
Summary:Abstract Given the success of immune checkpoint inhibitors and chimeric antigen receptor (CAR) T cells in clinical settings, the host immune system plays an important role in the recognition and targeting of tumor cells in cancer immunotherapy. As a result, there have been numerous advancements in immune cell therapy using human immune cells. However, recent evidence suggests that one type of immunotherapy alone is not effective for the treatment of cancer, particularly solid tumors. Thus, effective immunotherapy combinations, such as the combination of checkpoint inhibitors and immune cell therapy, are needed. This review focuses on hepatocellular carcinoma among other solid tumors and discusses the current status and future of immune cell therapy in cancer immunotherapy.
ISSN:1756-8722